A BPTF Inhibitor That Interferes with the Multidrug Resistance Pump to Sensitize Murine Triple-Negative Breast Cancer Cells to Chemotherapy
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252111346 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Melanie M Sinanian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Drug Resistance, Neoplasm, Molecular Docking Simulation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Department of Defense, Department of Defense Congressionally Mandated Breast Cancer Research Program, Virginia Commonwealth University Flow Cytometry Shared Resource.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is associated with a generally poor prognosis due to its highly aggressive and metastatic nature, lack of targetable receptors, as well as the frequent development of resistance to chemotherapy. We previously reported that AU1, a small molecule developed as an inhibitor of BPTF (bromodomain PHD finger-containing transcription factor), was capable of sensitizing preclinical models of TNBC to chemotherapy in part via the promotion of autophagy. In studies reported here, we identify an additional property of this compound, specifically that sensitization is associated with the inhibition of the P-glycoprotein (P-gp) efflux pump. In silico molecular docking studies indicate that AU1 binds to active regions of the efflux pump in a manner consistent with the inhibition of the pump function. This work identifies a novel chemical structure that can influence multidrug efflux, an established mechanism of drug resistance in TNBC, that has not yet been successfully addressed by clinical efforts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33516, Egypt.
- Philips Institute for Oral Health Research, School of Dentistry, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
- Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA 23298, USA.
- Department of Pharmacology, University of Texas Health Science Center, San Antonio, TX 78229, USA.
ORCID-Profile: Ahmed M Elshazly, Glen E Kellogg, April L Risinger, David A Gewirtz
Förderung
- United States Department of Defense
- Department of Defense Congressionally Mandated Breast Cancer Research Program
- Virginia Commonwealth University Flow Cytometry Shared Resource
- NIH-NCI Cancer Center Support
Zitieren
APA
Sinanian, M. M., Rahman, A., Elshazly, A. M., Neely, V., Nagarajan, B., Kellogg, G. E., Risinger, A. L., & Gewirtz, D. A. (2024). A BPTF Inhibitor That Interferes with the Multidrug Resistance Pump to Sensitize Murine Triple-Negative Breast Cancer Cells to Chemotherapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252111346
Vancouver
Sinanian MM, Rahman A, Elshazly AM, Neely V, Nagarajan B, Kellogg GE, et al. A BPTF Inhibitor That Interferes with the Multidrug Resistance Pump to Sensitize Murine Triple-Negative Breast Cancer Cells to Chemotherapy. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252111346
BibTeX
@article{Sinanian2024,
author = {Sinanian, Melanie M and Rahman, Afshan and Elshazly, Ahmed M and Neely, Victoria and Nagarajan, Balaji and Kellogg, Glen E and Risinger, April L and Gewirtz, David A},
title = {A BPTF Inhibitor That Interferes with the Multidrug Resistance Pump to Sensitize Murine Triple-Negative Breast Cancer Cells to Chemotherapy},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252111346}
}
EUVIMED